US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALPHA COGNITION INC

6.39

+0.41006.86%

Post-market: 6.390.00000.00%16:05 EDT

Volume:105.26K

Turnover:672.80K

Market Cap:102.37M

PE:-3.16

High:6.75

Open:6.00

Low:5.78

Close:5.98

Loading ...

Overview Company News Filings

Press Release: Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Alpha Cognition Strengthens Its Leadership Team With Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

THOMSON REUTERS

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Alpha Cognition FY 2024 GAAP EPS $(0.51) Misses $(0.08) Estimate

Alpha Cognition Inc: Qtrly Shr Loss $0.51

THOMSON REUTERS

Press Release: Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

THOMSON REUTERS

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

BUZZ-Alpha Cognition rises on commercial launch of Alzheimer's drug

Alpha Cognition Shares up 10.9% After Co Commercially Launches Alzheimer’s Disease Treatment

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE- Block, KBR, Sarepta Therapeutics

Alpha Cognition Launches Zunveyl for Treating Alzheimer's Disease; Shares Up Pre-Bell

MT Newswires Live

Alpha Cognition : Announces Commercial Launch of Zunveyl (Benzgalantamine) for Treatment of Mild to Moderate Alzheimer's Disease

THOMSON REUTERS

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

BUZZ-U.S. STOCKS ON THE MOVE- Tesla, Block, Alibaba Group

HC Wainwright Initiates Alpha Cognition at Buy With $20 Price Target

MT Newswires Live

BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACOG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACOG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACOG\",,,,,undefined,":{"symbol":"ACOG","market":"US","secType":"STK","nameCN":"ALPHA COGNITION INC","latestPrice":6.39,"timestamp":1746216000000,"preClose":5.98,"halted":0,"volume":105259,"hourTrading":{"tag":"盘后","latestPrice":6.39,"preClose":6.39,"latestTime":"16:05 EDT","volume":19,"amount":118.49,"timestamp":1746216310609},"delay":0,"floatShares":10409580,"shares":16019787,"eps":-2.019472,"marketStatus":"Closed","change":0.41,"latestTime":"05-02 16:00:00 EDT","open":6,"high":6.75,"low":5.7792,"amount":672804.5678,"amplitude":0.162341,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.019472,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":5.98,"postHourTrading":{"tag":"盘后","latestPrice":6.39,"preClose":6.39,"latestTime":"16:05 EDT","volume":19,"amount":118.49,"timestamp":1746216310609},"volumeRatio":1.618239},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACOG\",,,,,undefined,":{"symbol":"ACOG","floatShares":10409580,"roa":"-28.00%","roe":"-79.64%","lyrEps":-2.019472,"volumeRatio":1.618239,"shares":16019787,"dividePrice":0,"high":6.75,"amplitude":0.162341,"preClose":5.98,"low":5.7792,"week52Low":3.75,"pbRate":"2.47","week52High":7,"institutionHeld":0,"latestPrice":6.39,"eps":-2.019472,"divideRate":0,"volume":105259,"delay":0,"ttmEps":-2.019472,"open":6,"prevYearClose":5.89,"prevWeekClose":5.04,"prevMonthClose":5.52,"prevQuarterClose":5.06,"fiveDayClose":5.04,"twentyDayClose":4.99,"sixtyDayClose":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACOG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532074253","title":"Press Release: Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2532074253","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532074253?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:33","pubTimestamp":1746102780,"startTime":"0","endTime":"0","summary":"Conference Call Scheduled for May 15, 2025 4:30pm ET. Alpha Cognition Inc. , a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market.Following the release, management will host a conference call to review financial and operating results.To participate in the conference call, please use the dial-in information below:. Note, you can avoid long wait times for the operator by using the Call me feature and clicking the link below 15 minutes prior to the scheduled call start time:. This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward--looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG"],"gpt_icon":0},{"id":"2531035751","title":"Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531035751","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531035751?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Grapevine, Texas-- - Alpha Cognition, Inc. , today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Michael McFadden, CEO, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. .To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.About Alpha Cognition, Inc.Alpha Cognition is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease for which there are limited or no treatment options. On July 26, 2024, the Company received approval by the FDA of the Company’s New Drug Application  for ZUNVEYL  previously known as ALPHA-1062 oral tablet formulation for the treatment of mild-to-moderate Alzheimer’s disease. The Company will now focus on the development of commercial manufacturin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/alpha-cognition-inc-announces-participation-113000527.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-inc-announces-participation-113000527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","BK4585","ACOG","BK4561","BK4581","BK4588","ET","BK4139","BK4590"],"gpt_icon":0},{"id":"2526669565","title":"Alpha Cognition Strengthens Its Leadership Team With Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens","url":"https://stock-news.laohu8.com/highlight/detail?id=2526669565","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526669565?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA4NLMPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2526266598","title":"Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens","url":"https://stock-news.laohu8.com/highlight/detail?id=2526266598","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526266598?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288200,"startTime":"0","endTime":"0","summary":"VANCOUVER & DALLAS, April 10, 2025----Alpha Cognition Inc.  , a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership.\"On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team,\" said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. \"His experience across a range of diverse strategic roles will be highly instrumental as we continue to advance our commercial launch of ZUNVEYL and advance our sublingual program for mild-to-moderate Alzheimer’s Disease. Our board looks forward to working with Robert and leveraging his unique expertise.\". ZUNVEYL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-strengthens-leadership-team-123000065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4120","ACOG","BK4139","TISI"],"gpt_icon":0},{"id":"2524639121","title":"Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2524639121","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524639121?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:27","pubTimestamp":1743539220,"startTime":"0","endTime":"0","summary":"Dallas, Texas-- - Alpha Cognition Inc. : Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. . Alpha Cognition had a strong 2024 after raising $52.8M and uplisting to NASDAQ, significantly enhancing its capital base and market visibility. It completed commercial manufacturing for its lead product ZUNVEYL , secured a new U.S. patent extending exclusivity through 2044, and concluded phase one of a Department of Defense-funded study demonstrating the potential to treat head trauma from blasts.To view the full announcement, including downloadable images, bios, and more, click here.Successfully launched in U.S. LTC market; raised $52.8M, uplisted to Nasdaq , and secured patent protection through 2044.Signed $44M licensing deal for Asia; building international partnerships to diversify revenue and reduce risk.Strong start in $2B LTC market with experienced sales team; positive initial physician feedback driving awareness and adoption.Stonegate Capital Partners is a lead","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/stonegate-capital-partners-updates-coverage-202700071.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stonegate-capital-partners-updates-coverage-202700071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","USJW.SI","ACOG","MNQmain","PSQ","USAW.SI","NVIW.SI","SQQQ","QLD","TQQQ","BK4139","NQmain",".IXIC","QID"],"gpt_icon":1},{"id":"2523949655","title":"Alpha Cognition FY 2024 GAAP EPS $(0.51) Misses $(0.08) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949655","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949655?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:38","pubTimestamp":1743424693,"startTime":"0","endTime":"0","summary":"Alpha Cognition (NASDAQ:ACOG) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.08) by 537.5 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44560478/alpha-cognition-fy-2024-gaap-eps-0-51-misses-0-08-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG"],"gpt_icon":0},{"id":"2523949638","title":"Alpha Cognition Inc:  Qtrly Shr Loss $0.51","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949638?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:37","pubTimestamp":1743424635,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE10R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2523498379","title":"Press Release: Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523498379","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523498379?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424200,"startTime":"0","endTime":"0","summary":"--  Raised $52.8 million in gross proceeds in Q4 2024 to support the. upcoming ZUNVEYL commercial launch and Nasdaq uplisting .-- Completed commercial manufacturing to support the ZUNVEYL launch.-- Successfully completed the first phase of a pre-clinical bomb-blast study. funded by a Department of Defense grant, demonstrating benzgalantamine's. efficacy and safety in treating head trauma from simulated bomb blasts.-- Cash and cash equivalents of $48.6 million as of December 31, 2024,compared to $3.7 million as of September 30, 2024 and $1.4 million as of. December 31, 2023. At current cash utilization rates, the Company expects. Alpha Cognition Inc.   today announced its financial results for the fourth quarter and full year ended December 31, 2024.\"We closed 2024 on a strong note, securing capital to support the ZUNVEYL commercial launch and assembling an experienced leadership team, \" said Michael McFadden, Chief Executive Officer. \"In early 2025, we completed the manufacturing of th","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG"],"gpt_icon":0},{"id":"2523106789","title":"Alpha Cognition Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2523106789","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523106789?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:19","pubTimestamp":1743419940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACOG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 07:19 ET (11:19 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG"],"gpt_icon":0},{"id":"2520195617","title":"Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2520195617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520195617?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:30","pubTimestamp":1742416200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA6NMNSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2520196534","title":"Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2520196534","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520196534?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:30","pubTimestamp":1742416200,"startTime":"0","endTime":"0","summary":"Conference Call Scheduled for March 31, 2025 4:30pm ET. VANCOUVER, British Columbia & DALLAS, March 19, 2025----Alpha Cognition Inc. , a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market.Following the release, management will host a conference call to review financial and operating results.To participate in the conference call, please use the dial-in information below:. This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forwardlooking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-report-fourth-quarter-203000431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACOG"],"gpt_icon":0},{"id":"2520670948","title":"BUZZ-Alpha Cognition rises on commercial launch of Alzheimer's drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2520670948","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520670948?lang=en_us&edition=fundamental","pubTime":"2025-03-18 21:45","pubTimestamp":1742305522,"startTime":"0","endTime":"0","summary":"BUZZ-Alpha Cognition rises on commercial launch of Alzheimer's drug** Drug developer Alpha Cognition ACOG.O rises 12.5% to $5.91** ACOG says it has launched its oral therapy, Zunveyl, commercially to treat mild to moderate Alzheimer's disease ** Alzheimer's is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, which is the most common form of dementia affecting nearly 7 million people** Co says patients can now access the drug in 5 milligram , 10 mg and 15 mg doses** Zunveyl was approved by the FDA to treat AD in July 2024** Brokerage H.C. Wainwright estimates Zunveyl to generate $540 millon in peak annual sales in the US by the late 2030s** As of last close, ACOG down ~65% in the past 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL4N3Q10YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2520779976","title":"Alpha Cognition Shares up 10.9% After Co Commercially Launches Alzheimer’s Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520779976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520779976?lang=en_us&edition=fundamental","pubTime":"2025-03-18 21:33","pubTimestamp":1742304787,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q102Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2520671197","title":"BUZZ-U.S. STOCKS ON THE MOVE- Block, KBR, Sarepta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2520671197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520671197?lang=en_us&edition=fundamental","pubTime":"2025-03-18 21:05","pubTimestamp":1742303127,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Block, KBR, Sarepta TherapeuticsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL6N3Q10FU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1048588211.SGD","IE00BD4GTT62.SGD","BTU","LU0048597586.USD","LU1629966141.USD","CNR","SG9999001846.SGD","80700","LU1429558221.USD","SG9999000418.SGD","TSYW.SI","HBBD.SI","LU0516422952.EUR","LU0264606111.USD","IE00B1XK9C88.USD","LU0449515922.USD","LU1734074674.USD","BK4571","LU1629891620.HKD","SG9999000459.SGD","LU1105468828.SGD","XYZ","HK0000306701.USD","GENI","SG9999015986.USD","89988","ETR","LU1880383366.USD","SG9999001903.USD","SGXZ31699556.SGD","LU0572940350.SGD","TME","HTCD.SI","LU0327786744.USD","LCID","ACOG","LU0708995583.HKD","01698","KBR","SRPT","BE","LU0173614495.USD","HROW"],"gpt_icon":1},{"id":"2520676712","title":"Alpha Cognition Launches Zunveyl for Treating Alzheimer's Disease; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676712","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676712?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:50","pubTimestamp":1742302215,"startTime":"0","endTime":"0","summary":"Alpha Cognition (ACOG) said Tuesday it has commercially launched Zunveyl for the treatment of mild to moderate Alzheimer's disease.The company said the official commercial launch provides patients wit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2520675188","title":"Alpha Cognition : Announces Commercial Launch of Zunveyl (Benzgalantamine) for Treatment of Mild to Moderate Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2520675188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520675188?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:39","pubTimestamp":1742301560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q115P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2520675715","title":"Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2520675715","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520675715?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:30","pubTimestamp":1742301000,"startTime":"0","endTime":"0","summary":"ZUNVEYL is the first oral FDA-approved treatment for Alzheimer’s disease in the past decade. 32 person sales team hired to cover the $2 billion Long-Term-Care market. All launch activities delivered on-time and on-budget, positioning ZUNVEYL for success. VANCOUVER, British Columbia & DALLAS, March 18, 2025----Alpha Cognition Inc. , a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This milestone marks a major step forward in the company’s mission to provide innovative and accessible solutions for patients and caregivers — and to deliver new hope to the millions impacted by Alzheimer’s.ZUNVEYL  is a twice-daily treatment designed to address the cognitive symptoms of mild-to-moderate Alzheimer’s disease. By enhancing cholinergic function in the brain, ZUNVEYL supports memory, le","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-announces-commercial-launch-123000099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2520062434","title":"BUZZ-U.S. STOCKS ON THE MOVE- Tesla, Block, Alibaba Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2520062434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520062434?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:41","pubTimestamp":1742298095,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Block, Alibaba Group Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL6N3Q10GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["80700","09988","BABA","LU0261950983.USD","LU0259732245.USD","LU2471134796.USD","IE0002270589.USD","BK1588","LU0163747925.USD","LU0633140727.USD","LU0359202008.SGD","SG9999014880.SGD","89988","IE00BGV7N243.SGD","HTCD.SI","HROW","ACOG","LU0345770993.USD","LU2097828631.EUR","HBBD.SI","IE00B97KM107.HKD","TSLA","LU2756315664.SGD","BK4077","LU0315178854.USD","XYZ","LCID","BK4511","LU2360107168.USD","LU0633140560.USD","IE00B19Z3B42.SGD","IE00BZ08YS42.EUR","LU0327786744.USD","IE0034224299.USD","GENI","01698","LU0049853897.USD","IE00BZ08YR35.GBP","BK4535","LU0348783662.USD","LU1725190679.HKD","LU1066053197.SGD","TME","LU0588545904.SGD","LU0648948544.HKD","ETR","TSYW.SI"],"gpt_icon":1},{"id":"2520670623","title":"HC Wainwright Initiates Alpha Cognition at Buy With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2520670623","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520670623?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:02","pubTimestamp":1742295762,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Alpha Cognition at Buy With $20 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACOG"],"gpt_icon":0},{"id":"2520628128","title":"BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2520628128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520628128?lang=en_us&edition=fundamental","pubTime":"2025-03-18 18:58","pubTimestamp":1742295512,"startTime":"0","endTime":"0","summary":"BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc ACOG.O with \"buy\" rating and $20 PT, a 251.5% upside to the stock's last close** Says co's Alzheimer's disease drug Zunveyl, which is a \"next-generation symptomatic therapy\" has been shown to have a \"very low rate of GI side effects \" compared to 30-40% with existing cholinesterase inhibitors, and \"eliminate sleep disturbances\"** Says co has a \"finely tuned sales force\" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl** Co has a \"considerable long-term promise\" that is not reflected in its current stock price, which has been \"range-bound\" due to its relatively unknown status among US investors - brokerage** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s** Stock fell ~53% in 2024  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL4N3Q10QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACOG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"ACOG","fiscalQuarterEnding":"2024/12","expectedEps":-0.48,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":-0.51}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACOG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACOG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1742356800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACOG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACOG","date":"2025-05-01","current":-6.041541,"percent":0.54386,"low":-7.19781,"twenty":-6.496541,"median":-6.097993,"eighty":-5.5123,"high":-2.141254,"avg":-5.952135,"sd":0.755823,"marketCap":88429224},"quantilePoints":[{"date":"2024-11-15","current":-5.518409,"twenty":-5.518409,"median":-5.518409,"eighty":-3.492116,"marketCap":89218230.86},{"date":"2024-11-22","current":-6.095906,"twenty":-6.0779,"median":-6.040783,"eighty":-5.518409,"marketCap":89580038.69},{"date":"2024-11-29","current":-7.052964,"twenty":-6.126453,"median":-6.040783,"eighty":-5.612398,"marketCap":103759893.65},{"date":"2024-12-06","current":-6.313396,"twenty":-6.313396,"median":-6.095906,"eighty":-5.994414,"marketCap":92879715.89},{"date":"2024-12-13","current":-5.804676,"twenty":-6.309556,"median":-6.047523,"eighty":-5.928174,"marketCap":85395665.51},{"date":"2024-12-20","current":-3.792145,"twenty":-6.289737,"median":-6.03741,"eighty":-5.564347,"marketCap":55788252.01},{"date":"2024-12-27","current":-5.520861,"twenty":-6.27191,"median":-5.988356,"eighty":-5.512882,"marketCap":81220325},{"date":"2025-01-03","current":-6.174218,"twenty":-6.276367,"median":-6.018645,"eighty":-5.517304,"marketCap":90832197},{"date":"2025-01-10","current":-6.228664,"twenty":-6.280824,"median":-6.044156,"eighty":-5.518409,"marketCap":91633187},{"date":"2025-01-17","current":-6.479118,"twenty":-6.381986,"median":-6.114998,"eighty":-5.51988,"marketCap":95317738},{"date":"2025-01-24","current":-6.827574,"twenty":-6.433383,"median":-6.156206,"eighty":-5.546995,"marketCap":100444070},{"date":"2025-01-31","current":-6.533564,"twenty":-6.529208,"median":-6.174218,"eighty":-5.650957,"marketCap":96118728},{"date":"2025-02-07","current":-6.424671,"twenty":-6.533564,"median":-6.22812,"eighty":-5.770729,"marketCap":94516749},{"date":"2025-02-14","current":-6.228664,"twenty":-6.533564,"median":-6.228664,"eighty":-5.853338,"marketCap":91633187},{"date":"2025-02-21","current":-6.860242,"twenty":-6.561876,"median":-6.283111,"eighty":-5.928174,"marketCap":100924664},{"date":"2025-02-28","current":-6.533564,"twenty":-6.583654,"median":-6.313396,"eighty":-5.93555,"marketCap":96118728},{"date":"2025-03-07","current":-5.83665,"twenty":-6.561876,"median":-6.313396,"eighty":-5.93555,"marketCap":85866063},{"date":"2025-03-14","current":-6.130661,"twenty":-6.544453,"median":-6.27751,"eighty":-5.928174,"marketCap":90191406},{"date":"2025-03-21","current":-6.043547,"twenty":-6.542275,"median":-6.261332,"eighty":-5.928174,"marketCap":88909823},{"date":"2025-03-28","current":-5.782204,"twenty":-6.533564,"median":-6.228664,"eighty":-5.862785,"marketCap":85065074},{"date":"2025-04-04","current":-5.461466,"twenty":-6.533564,"median":-6.206886,"eighty":-5.804122,"marketCap":79938742},{"date":"2025-04-11","current":-4.56399,"twenty":-6.533564,"median":-6.185107,"eighty":-5.723114,"marketCap":66802511},{"date":"2025-04-17","current":-4.651549,"twenty":-6.533564,"median":-6.172541,"eighty":-5.520861,"marketCap":68084094},{"date":"2025-04-25","current":-5.538079,"twenty":-6.522675,"median":-6.13409,"eighty":-5.512882,"marketCap":81060122},{"date":"2025-05-01","current":-6.041541,"twenty":-6.496541,"median":-6.097993,"eighty":-5.5123,"marketCap":88429224}],"updateTime":1746240504918}}}